Showing results (71-80 of 108) with videos related to
Sort By:
Pageof 11
Biorxiv : the Preprint Server for Biology|November 19, 2025
A Tonic Signaling Code Predicts CAR-T Cell Efficacy in Diffuse Midline GliomaEmily B Deng, Xiaowen Zhong, Dazhuan Xin, et al.Neuro-Oncology|February 14, 2022
Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomasJustyna M Przystal, Chiara Cianciolo Cosentino, Sridevi Yadavilli, et al.JCO Precision Oncology|August 25, 2020
Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain TumorsCarl Koschmann, Yi-Mi Wu, Chandan Kumar-Sinha, et al.Molecular Cancer Therapeutics|August 16, 2020
Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen TherapyChristian K Werner, Uchechi J Nna, Hanshi Sun, et al.Acta Neuropathologica Communications|July 28, 2018
Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG RegistryHunter C Gits, Maia Anderson, Stefanie Stallard, et al.The Journal of Clinical Investigation|September 20, 2022
H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma modelsSantiago Haase, Kaushik Banerjee, Anzar A Mujeeb, et al.Neuro-Oncology|February 9, 2022
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline gliomaEvan Cantor, Kyle Wierzbicki, Rohinton S Tarapore, et al.Journal of Experimental & Clinical Cancer Research : CR|May 16, 2026
Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade gliomaLisa Mayr, Leah Mager, Lisa Gabler-Pamer, et al.Neuro-Oncology|May 13, 2022
Characteristics of children ≤36 months of age with DIPG: A report from the international DIPG registryAllison L Bartlett, Adam Lane, Brooklyn Chaney, et al.The Journal of Clinical Investigation|July 1, 2020
Everolimus improves the efficacy of dasatinib in PDGFRα-driven gliomaZachary Miklja, Viveka Nand Yadav, Rodrigo T Cartaxo, et al.Pageof 11